Pembrolizumab (Keytruda®) for oesphageal carcinoma or HER-2 negative gastroesophageal junction adenocarcinoma . HTA ID: 21032
Pembrolizumab (Keytruda®) for the first line treatment of adults with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS≥10.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 12/07/2021 |
| Rapid review completed | 05/08/2021 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care. |